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Abstract
Objectives—Recent studies have found that cases with oropharyngeal squamous cell carcinoma 
(OPSCC) positive for HPV16 genotype have better overall survival compared with cases positive 
for other HPV genotypes. We sought to further replicate these studies and determine if this 
relationship is modified by expression of p16 tumor suppressor protein.
Material and Methods—We identified 238 OPSCC cases from the Carolina Head and Neck 
Cancer Study (CHANCE) study, a population based case-control study. Tumors that tested positive 
solely for HPV16 genotype and no other genotypes with PCR were classified as HPV16-positive. 
Tumors positive for any other high-risk HPV genotype were classified as non-HPV16-positive. 
Expression of p16 in the tumor was determined with immunohistochemistry. Follow-up time was 
calculated from the date of diagnosis to date of death or December 31, 2013. Overall survival was 
compared with the Kaplan-Meier curves and log-rank test. Hazard ratios (HR) adjusted for 
smoking, alcohol use, sex, race, and age was calculated with the Cox proportional hazard 
regression.
Results—Cases with HPV16-positive OPSCC had better overall survival than cases with non-
HPV16-positive OPSCC (log-rank p-value: 0.010). When restricted to OPSCC cases positive for 
p16 expression, the same trend continued (log-rank p-value: 0.002). In the adjusted model, cases 
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with non-HPV16-positive OPSCC had greater risk of death compared to cases with HPV16-
positive tumors (HR: 1.92; 95% CI: 1.03, 3.60).
Conclusions—This finding indicates that HPV genotyping carries valuable prognostic 
significance in addition to p16 status and future survival studies of OPSCC should take into 
account differing HPV genotypes.
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Introduction
Over the last twenty years, the epidemiology of head and neck squamous cell carcinoma 
(HNSCC) has dramatically changed as a result of human papillomavirus (HPV). While head 
and neck cancers were traditionally associated with tobacco and alcohol use, approximately 
60–70% of oropharyngeal squamous cell carcinoma (OPSCC) cases are now driven by HPV 
[1, 2]. Additionally, HPV is an independent determinant of recurrence and survival in 
OPSCC, in which HPV-positive cancer cases have better outcomes than HPV-negative 
cancer cases [1, 3, 4].
HPV16 is the most common genotype associated with OPSCC [5, 6]. Other HPV genotypes 
such as HPV33, HPV18 and HPV35, have been associated with OPSCC but their relation 
with clinical outcomes are less well known [5]. Previous studies have suggested patients 
with HNSCC positive for HPV16 genotype have better survival compared with patients with 
tumors that are positive with other HPV genotypes [6–9].
Immunohistochemical expression of p16, a tumor suppressor protein, is a widely accepted 
biomarker for assessing HPV status and is considered the standard for treatment 
stratification in clinical trials [10]. Following mucosal infection, two HPV-encoded 
oncoproteins, E6 and E7, inactivate tumor suppressor genes TP53 and pRb, respectively. 
This induces downstream overexpression of the p16 protein [11]. Polymerase chain reaction 
(PCR) can also be used for HPV identification in tumor cells. PCR is more sensitive than 
p16 immunohistochemistry and allows for identification of specific HPV genotypes, thus 
adding another dimension to the assessment of HPV status [12].
We sought to assess if survival differs by HPV genotype determined by PCR in the cases 
from a large population-based study, the Carolina Head and Neck Cancer Study (CHANCE). 
We hypothesize OPSCC cases positive for genotypes other than HPV16 will have worse 
survival than those with HPV16-positive tumors and this trend will hold among OPSCC 
positive for p16 expression.
Material and Methods
Study Population
Subjects for this longitudinal survival analysis were cases from CHANCE, the population-
based case-control study. Cases were diagnosed with first primary squamous cell carcinoma 
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of the oral cavity, pharynx, and larynx from January 1, 2002 to February 28, 2006, aged 20 
to 80 years at diagnosis, and resided in a 46-county region in central North Carolina. Benign 
tumors, carcinomas in situ, papillary thyroid carcinomas, and adenoid carcinomas were 
excluded. All available cases of oropharyngeal tumors and a sample of non-oropharyngeal 
tumors were selected for p16 immunohistochemistry and HPV detection by PCR (N = 492). 
Cases with lip and hypopharynx cancers, cases for whom the hospital would not release 
tumor blocks, and cases in which interviews were completed by a proxy were also excluded 
from p16 immunohistochemistry and HPV typing. However, since HPV has only been 
consistently associated with oropharyngeal cancer, all other sites were excluded (N = 254), 
resulting 238 OPSCC cases for analysis. This research was approved by the institutional 
review board at the University of North Carolina at Chapel Hill.
Outcome assessment
CHANCE data were linked to the National Death Index based on name, social security 
number, date of birth, sex, race, and state of residence to identify deaths through December 
31, 2013. The National Death Index is a national file of identified death record information, 
including cause of death compiled from computer files submitted by State Vital Statistics 
offices. Greater than 75% of the cases in CHANCE were perfect or near-perfect matches on 
social security number, date of birth, and sex. The remaining near-matches were confirmed 
by examining the United States Social Security Death Index and obituaries on newspaper 
websites.
Questionnaire and Clinical Assessment
Demographic and risk factor information were collected using a structured questionnaire 
during an in-home visit conducted by trained nurse-interviewers. Demographic variables of 
interest include: age, race, sex, smoking (<10 pack-years and ≥10 pack-years) and alcohol 
(<1 drink/week and ≥1 drinks/week).
Clinical information such as TNM classification and cancer treatments were abstracted from 
the subjects’ medical records and reviewed independently by a head and neck surgeon and a 
pathologist. Only oropharynx cancers (C01.9, C02.4, C05.1, C05.2, C09.0, C09.1, C09.8, 
C09.9, C10.0-C10.4, C10.8, and C10.9) were included in this analysis.
HPV and p16 Typing
The International Agency for Research on Cancer performed HPV typing and centralized 
pathology review plus evaluation of p16 expression by immunohistochemistry. HPV 
infection was determined using a HPV-type-specific E7 PCR bead-based multiplex 
genotyping assay (E7-MPG).[13] We included the high-risk genotypes (HPV16, HPV18, 
HPV26, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV53, HPV56, 
HPV58, HPV59, HPV66, HPV68, HPV70, HPV73 and HPV82) as well as two low-risk 
genotypes (for the following genotypes: HPV6 and HPV11) for PCR. HPV genotype was 
classified into two categories: HPV16-positive and non-HPV16 positive. Tumors were 
classified as HPV16-positive if they were positive for HPV16 genotype only. Tumors 
positive for any high-risk genotype were classified as non-HPV16-positive. 
Immunocytochemistry for p16 was performed according to the protocol provided with the 
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CINtec Histology p16INK4a Kit (9511, mtmlabs) for the detection of the p16 antigen on 
slides prepared from formalin-fixed, paraffin-embedded resections. The expression was 
scored through evaluation and semi-quantitative scoring of two variables: the percentage of 
stained cells (0% = 0, 1–10% = 1, 11–50% = 2, 51–80% = 3, 81–100% = 4) and the intensity 
of the nucleic or cytoplasmic staining (none = 0, weak = 1, moderate = 2, strong = 3). The 
two scores were then multiplied to yield the composite score, ranging from 0–12. Composite 
scores of 4 or greater were considered positive for p16 expression and scores of 0 to 3 were 
considered negative for p16 expression.
Statistical Analysis
We calculated overall survival as time from diagnosis to either date of death due to any 
cause or censoring on December 31, 2013, whichever came first. Differences in covariate 
distributions by HPV or p16 status were tested by two-sided Pearson chi-square tests or by 
Fisher exact tests when cells are sparse. Kaplan-Meier overall survival plots were 
constructed and log-rank p-values were calculated. Hazard ratios (HRs) for the independent 
effects HPV genotype with overall survival among all OPSCC cases were estimated by Cox 
proportional hazards regression adjusted for sex, age, race, smoking, and alcohol. These 
potential confounders were selected with a causal diagram or due to its relationship with 
head and neck cancer. We estimated HRs with a Cox proportional hazard regression that 
adjusted for treatment and N and T classification in addition to the previous variables. The 
other race classification and cases that are M1 were excluded from this multivariable 
analysis due to small numbers. The proportional hazards assumption for HPV genotype was 
tested and satisfied. Alpha of 0.05 was used for all statistical testing and confidence interval 
(CI) calculations. All statistical analyses were implemented using SAS 9.4 (SAS Institute, 
Cary, NC).
Results
The demographic and clinical variables were not significantly different by HPV genotype in 
OPSCC (Table 1). However, several key clinical variables varied by HPV genotype. HPV16-
positive cases were more likely to have smoked more than 10 pack-years (61.9%) compared 
with non-HPV16-positive case (42.9%). HPV16-positive OPSCCs were also more likely to 
have p16 expression than non-HPV16-positive OPSCCs (p-value: 0.177).
Table 2 displays the descriptive results for HPV genotype by p16 expression in OPSCC. As 
expected, the OPSCCs were mostly HPV-positive (73.4%). About 12.5% of HPV-positive 
oropharynx tumors were non-HPV16-positive. Most of the oropharynx tumors that are 
HPV16-positive also have p16 expression (88.3%). However, about 30% of the OPSCC 
negative for p16 expression were positive for HPV with PCR.
As seen in the Kaplan-Meier curve (Figure 1), cases with HPV16-positive OPSCC had 
better overall survival than cases with non-HPV16-positive OPSCCs (log-rank p-value: 
0.010). Five-year survival for cases with HPV16-positive OPSCCs was 71.4% while cases 
with HPV-positive-other OPSCCs (57.1%) and HPV-negative OPSCCs (50.0%) had similar 
5-year survival. When restricted to OPSCCs with positive expression of p16, cases with non-
HPV16-positive OPSCCs had worse survival (62.5%) than cases with HPV16-positive 
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OPSCCs (78.6%; Log-rank p-value: 0.002). Among cases with p16-negative OPSCCs, 
survival did not differ by HPV genotype (log-rank p-value: 0.751).
In the multivariable Cox regression analysis (Table 3) adjusting age, race, sex, smoking and 
alcohol, both cases with non-HPV16-positive OPSCCs (Hazard ratio (HR): 1.92; 95% CI: 
1.03, 3.60). When including T classification, N classification and treatment in the 
adjustment, there is little difference in the HR (Table 3).
Although not significant, among OPSCC that tested positive for p16 expression, cases with 
non-HPV16-positive (n = 16) tumors had greater risk of death compared with HPV16-
positve (n = 135) tumors (HR: 1.82; 95% CI: 0.82, 4.02). The HR remains similar after 
adjustment for T classification, N classification and treatment. Among OPSCC negative for 
p16 expression, non-HPV16-positive OPSCC may have a slightly increased risk of death 
compared with HPV16-positive (n = 20) OPSCC (HR: 1.40; 95% CI: 0.39, 4.99). However, 
when including T classification, N classification and treatment into the model, the HRs are 
attenuated (HR: 1.28; 95% CI: 0.33, 5.05).
Discussion
The purpose of this study is to determine if HPV genotype is associated with differences in 
survival for patients with OPSCC and if this trend holds for oropharyngeal tumors positive 
for p16 expression. Our results replicated previous findings that cases with HPV16 genotype 
have improved survival, even among cases with OPSCC positive for p16 expression. 
However, among OPSCC negative for p16 expression HPV genotype may not be associated 
with overall survival. This survival benefit for the HPV16-genotype holds true in the Cox 
proportional hazard regression adjusting for stage at presentation and treatment as well as 
other confounders. These results suggest that the survival benefit of HPV-positivity may be 
restricted with HPV16 genotype only and HPV genotype may provide valuable prognostic 
information and help guide optimal treatment.
Increased survival for HPV-positive OPSCC, regardless of HPV genotype, is well 
documented. However, few studies have examined survival trends in cases stratified by HPV 
genotype [7–9]. Bratman et al. demonstrated a significant survival benefit for HPV16-
positive cases (N = 61) compared with non-HPV16-positive (N = 12) and HPV-negative (N 
= 442) among all HNSCC (log-rank: <0.001) with cases from The Cancer Genome Atlas 
[7]. The authors concluded that validation of these results specifically in OPSCC patients is 
warranted to inform treatment decisions. Although we also see a significant association by 
HPV genotype across all sites (results not shown), we concentrated on OPSCC since the 
prognostic value of HPV status in non-oropharynx tumors has yet to be established [14, 15]. 
Two other groups in the United States conducted studies comparing HPV genotypes in 
OPSCC. A study by Varier et al. found HPV16-positive OPSCC from the Icahn School of 
Medicine at Mount Sinai had non-significantly better survival than patients with non-
HPV16-positive OPSCC (n=27) [9]. Another study from Centers for Disease Control Cancer 
Registry Sentinel Surveillance, a cancer registry-based residual tissue, also found decreased 
survival for cases with non-HPV16-positive OPSCC compared to HPV16-positive OPSCC 
even after adjustment for covariates [6]. However these studies did not examine HPV 
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genotype among cases that were p16-positive, the most clinically used indicator of HPV 
driven disease due to its downstream position in the HPV tumorigenesis pathway.
The exact mechanisms underlying the decreased survival of cases with non-HPV16-positive 
OPSSC have yet to be fully elucidated. A recent study found the HPV18 genotype induced 
colony growth primary human keratinocytes more effectively than HPV16 or HPV31 [16]. 
This could be due to decreased apoptosis and thus increased carcinogenicity of HPV18. Rat 
fibrosarcomas transfected with HPV18 had significantly less apoptosis than fibroscaromas 
transfected with HPV16 [17]. Similarly, the HPV18 LCR-E6-E7 region was approximately 
10- to 50-fold more active than that of HPV16 [18].
Examining the association between HPV genotype and survival is an important step in the 
development of individualized oncologic treatment plans for patients with OPSCC. 
Recently, several clinical trials have been developed to enroll HPV-positive OPSCC patients 
in trials with de-intensified therapy [19]. Improved survival and oncologic outcomes with 
HPV-positive OPSCCs are the principal factors underlying the development of these trials. 
Current treatment regimens used in clinical practice are associated with significant toxicities 
and treatment related morbidity [20]. Further, since patients with HPV-positive tumors have 
improved oncologic outcomes and are living longer after diagnosis and treatment, patients 
must live with these adverse treatment-related effects for longer periods of time. Thus, 
identifying HPV-positive low-risk patients who are candidates for trials with de-intensified 
treatment in which toxicity is minimized while clinical outcomes are maximized has 
important clinical implications.
Currently, many of the clinical trials that de-intensify treatment for patients with HPV-
positive tumors use p16 expression alone to stratify patients [19]. Previous studies have 
suggested that p16 immunohistochemistry is the best method for patient risk-stratification 
since it is widely available [21, 22]. However, based upon our results, about 12% of cases 
have non-HPV16-positive and HPV-negative tumors. Treatment de-intensification based on 
p16 immunohistochemistry alone could adversely affect this small proportion of patients 
who have worse outcomes and may not receive appropriate treatment consistent with 
standard of care if included in trials with de-intensified treatment. Our study further 
emphasizes a differential survival based upon HPV genotype and suggests a clinical and 
biological difference by HPV genotype may exist. Additional studies should be conducted to 
determine if this discrepancy is due to other characteristics associated with HPV status or 
possible false positives due to the high sensitivity of PCR and further clarify if this 
association is demonstrated in populations with larger sample sizes of OPSCC p16-positive 
patients.
Our study has some limitations and strengths. First, similar to previous studies, there are 
relatively few cases of OPSCC that are non-HPV16-positive. Due to this limitation, we are 
unable to further explore the relationship between other HPV genotypes specifically and 
survival and their relationship with p16 expression. It is also possible that the non-HPV16 
genotypes are false-positives. However, we are the first study to have both HPV genotype 
and p16 from a large population-based cohort of cases and the results were similar when 
restricted to p16-positive OPSCC. Additionally, because this study was conducted prior to 
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HPV becoming widely accepted as a risk-factor for OPSCC, this HPV status should not 
affect treatment of these cases. All cases were recruited from North Carolina, which would 
reduce the variability in the treatment and thus impacting survival. Lastly, we are only able 
to study overall survival as a proxy for disease-specific survival. However, since this case-
control study was linked to the National Death Index, we have reasonably good measure of 
the outcome for all the cases from 7 to 12 years after diagnosis.
In conclusion, we have demonstrated that among OPSCC positive for p16 expression, 
HPV16-positive tumors have greater survival compared with OPSCC that are non-HPV16-
postive. This finding indicates that HPV genotyping carries valuable prognostic significance 
and is especially noteworthy given the recent clinical trials for de-intensification of treatment 
for HPV-positive OPSCC patients based upon p16 expression. Because both non-HPV16-
positive and HPV-negative cases positive for p16 expression have worse survival, even with 
standard of care treatment, treatment de-intensification may not represent a viable option for 
these subsets of cases with p16 expression. Overall, due to these differences in survival, 
future studies should distinguish between HPV16-positive cancers and non-HPV16-positive 
cancers when evaluating treatment efficacy for OPSCC positive for p16 expression. 
However, due to our small sample size, additional studies should be conducted to replicate 
these results.
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Highlights
• First to study the prognostic significance of non-HPV16 genotypes 
with p16 status.
• HPV16-positve oropharynx tumors have better survival than non-
HPV16-positive genotypes
• The survival benefit for HPV16-positve genotypes holds for tumors 
positive for p16, but not for p16-negative tumors
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Figure 1. 
Kaplan-Meier curve for HPV16-positive, non-HPV16-positive and HPV-negative OPSCC 
for A) all OPSCC B) OPSCC positive for p16 expression and C) OPSCC negative for p16 
expression
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Table 2
Distribution of HPV genotype in OPSCC
p16-positive
N = 163
p16-negative
N = 84
N (%) N (%)
HPV-positive
6 0 1 (1.2)
11 0 0
16 144 (88.3) 22 (26.2)
18 4 (2.5) 0
26 1 (0.6) 0
31 0 0
33 4 (2.5) 0
35 5 (3.1) 3 (3.6)
39 0 1 (1.2)
58 1 (0.6) 0
59 2 (1.2) 0
82 0 0
HPV-negative 7 (4.3) 59 (70.2)
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